| |
Wednesday, March 26, 2025 | 12pm ET / 9am PT Join us for this exclusive webinar to gain actionable insights from industry experts on the top challenges of HCP engagement and latest strategies for driving commercial success. Register today. 
|
|
Today’s Big NewsMar 11, 2025 |
|
Wednesday, March 26, 2025 | 2pm ET / 11am PT Understanding a molecule’s characteristics early in development helps minimize challenges and streamline the path to manufacturing. This webinar will explore key considerations in developability assessment, the role of in silico tools in molecular evaluation, and strategies for improving data security in the process. Register now to join us. 
|
|
| By James Waldron Pfizer and Arvinas’ estrogen receptor degrader has failed a key part of its first phase 3 test, although the companies have pointed to success in a subpopulation to suggest the therapy still has a path to regulators. |
|
|
|
By Angus Liu More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling itself to partner Bristol Myers Squibb. |
By Darren Incorvaia Biotech incubator Flagship Pioneering has uncorked its latest company. Lila Sciences is looking to use $200 million in seed funding to develop advanced artificial intelligence that can power fully autonomous research labs. |
By Gabrielle Masson Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter company to discontinue development of the program. |
|
Thursday, March 27, 2025 | 3pm ET / 12pm PT The way healthcare providers are navigating medication access is evolving rapidly, making it critical for pharma brands to keep up. Join us for this deep dive into the latest strategies and tools that can be seamlessly integrated into HCP workflows, while also driving efficiency, improved patient outcomes, and measurable impact. Register now. 
|
|
By James Waldron Coherus BioSciences will see its workforce shrink once again as a result of the recent sale of its Neulasta biosimilar to Accord BioPharma. |
By Darren Incorvaia Boston biotech Beam Therapeutics has announced initial data from a phase 1/2 trial of its gene therapy for a genetic lung and liver disease, with no serious adverse events reported among the nine patients dosed so far. |
By Nick Paul Taylor Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable of reaching targets beyond the liver. |
By Darren Incorvaia Immunocore’s big swing for a functional HIV cure has cleared its first hurdle. No serious adverse events were tied to the British biotech’s bispecific T-cell engager in a phase 1/2 trial, and the investigational treatment also reduced virus levels in the blood of three patients living with HIV. |
By Angus Liu Roche has recently launched a “fundamental reorganization” of Spark Therapeutics, the gene therapy unit that the Swiss pharma bought for $4.3 billion in 2019. |
By Darren Incorvaia Montreal-based CRO Innovaderm Research has rebranded with immediate effect to Indero, the latest change in an effort to become dually focused on both rheumatology and dermatology. |
By Dave Muoio An annual list of the 10 biggest threats to patient safety highlights the risk of doctors ignoring or dismissing patient concerns, either due to clinicians' unrecognized bias or time constraints. Other top concerns cited by the healthcare safety group included insufficient AI governance and medical misinformation. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we dig into several of the biggest private funding rounds in biotech last year and discuss the shifting VC landscape. |
|
|---|
|
|
|
Thursday, April 3, 2025 | 11am ET / 8am PT Join us for an insightful webinar on the latest advancements in cell and gene therapy, focusing on the innovative Cas9-CLIPT (Cleaved, Linearized with Protein Template) technology. Learn more about this groundbreaking technology designed to improve the efficiency of genome editing. Register now. 
|
|
Whitepaper Read about four trends that will shape the innovations, therapies, & market landscape in oncology during 2025 & beyond. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Discover how to revolutionize your vaccine trials with Avacare's latest white paper. Gain exclusive access to innovative, data-driven recruitment strategies that ensure diverse, efficient, and high-quality vaccine trials. Sponsored by: Avacare Clinical Research Network |
Whitepaper Develop your CAR molecule faster Sponsored by: Cell Signaling Technology |
| Submissions Open Early August |
|
|
| |
|
